Pds biotech announces interim 24-month survival rate of 74% in immune checkpoint inhibitor naÏve head and neck cancer patients treated with pds0101 in combination with keytruda® (pembrolizumab)

Princeton, n.j., oct. 03, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced updated interim data based on an august 2nd cut off from the versatile-002 phase 2 clinical trial evaluating pds0101 in combination with merck's anti-pd-1 therapy, keytruda® (pembrolizumab), in patients with unresectable, recurrent, or metastatic hpv16-positive head and neck squamous cell carcinoma (hnscc). versatile-002 is investigating two patient populations whose cancer has returned or spread – ici naÏve and ici refractory. the ici naÏve group had not responded to standard-of-care treatments but had not yet been treated with an ici. the ici refractory group included patients who had not responded to multiple prior treatments, including ici therapy. data presented at asco was based on a january 13th cut off.
PDSB Ratings Summary
PDSB Quant Ranking